Disruption of IL-18 signaling via engineered IL-18BP biologics alleviates experimental cholestatic liver disease.

APB-R3 - AprilBio

http://www.ncbi.nlm.nih.gov/pubmed/37774670

Dong-Hyun Kim; Jaekyu Han; Jinjoo Park; Kyeong-Jin Lee; Sang-Hoon Cha; Seung Goo Kang; Sun-Mi Kim; Susan Chi; Yewon Bang; Yong-Hyun Han

Sep 30, 2023